非奈利酮在合并2型糖尿病的慢性肾脏病患者中按基线胰岛素抵抗分层的结局
基于FIDELITY研究(N=13,026)的二次分析,按估算葡萄糖处置率(eGDR)中位数4.1 mg/kg/min将患者分为胰岛素抵抗组(eGDR低于中位数)和胰岛素敏感组(eGDR不低于中位数)。胰岛素抵抗与心血管事件发生率升高相关,但与肾脏结局无关,且未改变非奈利酮对心血管或肾脏结局的疗效。
要点
- eGDR低于中位数(胰岛素抵抗)者心血管事件发生率高于eGDR不低于中位数者。
- eGDR与肾脏结局无显著关联。
- 非奈利酮对心血管和肾脏结局的效应在eGDR亚组间无显著异质性。
核心结论
- 胰岛素抵抗与心血管风险升高相关,但与肾脏风险无关,且未改变非奈利酮的疗效。
研究设计与样本
- FIDELITY研究(N=13,026)的二次分析,纳入合并2型糖尿病的慢性肾脏病患者,随机接受非奈利酮或安慰剂治疗,eGDR可计算者共12,964例。
主要发现
- eGDR中位数为4.1 mg/kg/min。
- eGDR低于中位数(胰岛素抵抗)者心血管事件发生率高于eGDR不低于中位数者:非奈利酮组5.18 vs 3.47/100患者年,安慰剂组6.34 vs 3.76/100患者年。
- eGDR与肾脏结局无关。
- 非奈利酮对心血管结局的效应在eGDR低于中位数组HR 0.81(95%CI 0.72-0.92)、不低于中位数组HR 0.92(95%CI 0.79-1.06),交互作用P=0.23。
- 非奈利酮对肾脏结局的效应在eGDR低于中位数组HR 0.84(95%CI 0.68-1.02)、不低于中位数组HR 0.70(95%CI 0.58-0.85),交互作用P=0.28。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To explore whether insulin resistance, assessed by estimated glucose disposal rate (eGDR), is associated with cardiorenal risk and whether it modifies finerenone efficacy. RESEARCH DESIGN AND METHODS: In FIDELITY (N = 13,026), patients with type 2 diabetes, either 1) urine albumin-to-creatinine ratio (UACR) of ≥30 to <300 mg/g and estimated glomerular filtration rate (eGFR) of ≥25 to ≤90 mL/min/1.73 m2 or 2) UACR of ≥300 to ≤5,000 mg/g and eGFR of ≥25 mL/min/1.73 m2, who also received optimized renin-angiotensin system blockade, were randomized to finerenone or placebo. Outcomes included cardiovascular (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure) and kidney (kidney failure, sustained decrease of ≥57% in eGFR from baseline, or renal death) composites. eGDR was calculated using waist circumference, hypertension status, and glycated hemoglobin for 12,964 patients. RESULTS: Median eGDR was 4.1 mg/kg/min. eGDR <median (insulin resistant) was associated with higher cardiovascular event incidence regardless of treatment versus ≥median (insulin sensitive) (incidence rate/100 patient-years of 5.18 and 6.34 [for finerenone and placebo] vs. 3.47 and 3.76 [for finerenone and placebo], respectively). However, eGDR was not associated with kidney outcomes. There was no significant heterogeneity for effects of finerenone by eGDR on cardiovascular (<median: hazard ratio [HR] 0.81, 95% CI 0.72-0.92; ≥median: HR = 0.92, 95% CI 0.79-1.06; P interaction = 0.23) or kidney outcomes (<median: HR = 0.84, 95% CI 0.68-1.02; ≥median: HR = 0.70, 95% CI 0.58-0.85; P interaction = 0.28). Overall, finerenone demonstrated similar safety between subgroups. Sensitivity analyses were consistent. CONCLUSIONS: Insulin resistance was associated with increased cardiovascular (but not kidney) risk and did not modify finerenone efficacy.
引用
- Ebert T, Anker SD, Ruilope LM, et al. Outcomes With Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Baseline Insulin Resistance. Diabetes Care. 2024. PMID: 38151465. doi:10.2337/dc23-1420
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。